Frazier Healthcare Partners Promotes Three Life Sciences Investment Professionals

MENLO PARK, Calif.--()--Frazier Healthcare Partners, a leading healthcare-focused investment firm founded in 1991, has announced the promotions of three investments professionals on the Life Sciences team: Dan Estes, Ph.D. to Partner; Remy Durand, Ph.D. to Vice President; and Jamie Brush, M.D. to Senior Associate.

Dan Estes joined the Frazier Life Sciences team in 2011 and serves on the boards of Semnur Pharmaceuticals and Outpost Medicine. He has also played key roles in Frazier’s investments in Acerta Pharma (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Cidara Therapeutics (NASDAQ: CDTX), Precision Dermatology (acquired by Valeant), Millendo Therapeutics and Entasis Therapeutics, among others.

Remy Durand joined Frazier in 2015 and has been involved with all life sciences deals since that time. He is an observer on the boards of Alpine Immune Sciences, Aptinyx Inc., Iterum Therapeutics and Zavante Therapeutics.

Jamie Brush joined the Frazier Life Sciences team in 2016. Prior to joining Frazier, he was a management consultant at Boston Consulting Group. He received his M.D. from the University of Southern California.

Managing General Partner Patrick Heron stated, “We are very happy to see the continued progress of our investment team. Dan, Remy and Jamie each greatly contributed to our record year of life sciences realizations after the launch of our initial Life Sciences fund at the beginning of 2016.”

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners has been a leading U.S.-based healthcare-focused investment firm providing private growth capital to healthcare companies. The firm has more than $2.9 billion in committed capital under management and has made investments in more than 170 companies ranging from early-stage venture investments to growth buyouts of profitable lower middle market companies. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging their deep domain expertise and expansive network of healthcare executives, advisors and industry thought leaders. Frazier Life Sciences Fund and Frazier Healthcare Growth Buyout Fund are the two vehicles utilized to make investments in early stage life sciences companies and lower middle market profitable growth buyout companies, respectively. While these strategies target companies in distinctively different market segments and stages of development, both investment teams leverage the firm's rich 26-year history to identify and partner with exceptional management teams to develop category-leading companies. Frazier has offices in Seattle, Wash., and Menlo Park, Calif., and invests broadly across the United States, Canada and Europe.

For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

Contacts

Frazier Healthcare Partners
Liz Park, 650.319.1831
liz.park@frazierhealthcare.com

Contacts

Frazier Healthcare Partners
Liz Park, 650.319.1831
liz.park@frazierhealthcare.com